Despite these effects, the outcomes reported by Suda,Kuzumaki indicated that ghrelin has PDimproving effects only in the early stage of the disease resembledby haloperidol-induced transient blockage of dopaminergic (DA) transmission.However, this study used only a single dose of ghrelin to study itseffects; thus, the obtained data are still equivocal, and more investigationsmay need to take place to confirm the spectrum by which AG can aidin PD treatment. Here, GHRL is linked to Parkinson disease.